News
VANI
1.080
+8.00%
0.080
Vivani Medical Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
Vivani Medical Price Target Cut to $3.50/Share From $4.00 by HC Wainwright & Co.
Dow Jones · 3d ago
Vivani Medical price target lowered to $3.50 from $4 at H.C. Wainwright
TipRanks · 4d ago
Weekly Report: what happened at VANI last week (0323-0327)?
Weekly Report · 5d ago
Vivani: Solid Funding Runway and Strategic Catalysts Underpin Buy Rating
TipRanks · 6d ago
Vivani Medical Q4 EPS $(0.09) Beats $(0.10) Estimate.
Benzinga · 03/26 20:49
Vivani Medical GAAP EPS of -$0.43 misses by $0.01
Seeking Alpha · 03/26 20:24
*Vivani Medical 4Q Loss $6.6M >VANI
Dow Jones · 03/26 20:20
Vivani Medical FY2025 net loss widens 13.2% to $26.6 million; loss per share holds at $0.43
Reuters · 03/26 20:18
VIVANI MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Reuters · 03/26 20:16
Press Release: Vivani Medical Reports Fourth -3-
Dow Jones · 03/26 20:16
Press Release: Vivani Medical Reports Fourth -2-
Dow Jones · 03/26 20:16
Vivani Medical: Q4 Earnings Snapshot
Barchart · 03/26 15:44
Weekly Report: what happened at VANI last week (0316-0320)?
Weekly Report · 03/23 09:04
Insider Makes Bold Move With Major Vivani Medical Stock Purchase
TipRanks · 03/17 02:07
Weekly Report: what happened at VANI last week (0309-0313)?
Weekly Report · 03/16 09:04
Weekly Report: what happened at VANI last week (0302-0306)?
Weekly Report · 03/09 09:04
Weekly Report: what happened at VANI last week (0223-0227)?
Weekly Report · 03/02 09:04
Weekly Report: what happened at VANI last week (0216-0220)?
Weekly Report · 02/23 09:04
Top Vivani Medical Insider Makes Bold Multi-Million Dollar Move
TipRanks · 02/18 02:01
More
Webull provides a variety of real-time VANI stock news. You can receive the latest news about Vivani Medical through multiple platforms. This information may help you make smarter investment decisions.
About VANI
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company, developing miniature, ultra-long-acting drug implants. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.